Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of GSK2646264 in Cutaneous Lupus Erythematosus Subjects

NCT02927457 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

11

Enrollment

INDUSTRY

Sponsor class

Conditions

Lupus Erythematosus, Cutaneous

Interventions

DRUG: GSK2646264 1%
DRUG: Placebo

Sponsor

GlaxoSmithKline